Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical laboratory clinical research organisation (CRO) that develops, validates and delivers complex and custom-designed assays for biopharmaceutical companies. Its remit is to translate difficult scientific questions into robust assays suitable for clinical trial sample analysis, supporting drug development programmes from discovery through to regulatory submission. The company reports more than 20 years of biomarker and bioanalytical science experience.

The technical offering spans biomarker identification and development, large and small molecule clinical bioanalysis, cell biology services including flow cytometry and ELISpot, and genomic services, alongside assay development and validation. Together these capabilities cover the analytical work required to measure drug and biological response across a clinical trial's lifecycle.

The firm employs over 200 staff, of whom approximately 60% are scientists, and operates three laboratory locations: Manchester in the United Kingdom, Turku in Finland and Cape Town in South Africa, serving customers worldwide. Synexa has been backed by Gilde Healthcare, a specialised healthcare investor, since 2019. It describes its purpose as improving the quality of human health through the services it provides, and states that it fosters scientific innovation and excellence across its staff.